Osteopontin Involves Cisplatin Resistance and Poor Prognosis in Oral Squamous Cell Carcinoma

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Luo, Sheng Dean ^a,b,c   Chen, Yi Ju ^d   Liu, Chien Ting ^a,b,c   Rau, Kun Ming ^a,b   Chen, Yi Ching ^a,b   Tsai, Hsin Ting ^a,c   Chen, Chang Han ^a,e   Chiu, Tai Jan ^a,b,c,e  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d I SHOU UNIVERSITY   (Taiwan)

^e NATIONAL CHI NAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; OSTEOPONTIN; PARAFFIN; ANTINEOPLASTIC AGENT; TAXOID; TUMOR PROTEIN;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MOUTH SQUAMOUS CELL CARCINOMA; MTT ASSAY; ORAL CANCER CELL LINE; SEX DIFFERENCE; TREATMENT RESPONSE; TUMOR BIOPSY; ADULT; AGED; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MOUTH NEOPLASMS; PATHOLOGY; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM PROTEINS; OSTEOPONTIN; SURVIVAL RATE; TAXOIDS;

EID: 84944215592     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/508587     Document Type: Article

References (42)

1. C.-Y. Chien, C.-Y. Su, H.-C. Chuang et al., "Comprehensive study on the prognostic role of osteopontin expression in oral squamous cell carcinoma," Oral Oncology, vol. 45, no. 9, pp. 798-802, 2009
2. E. S. Kim, M. Kies, and R. S. Herbst, "Novel therapeutics for head and neck cancer," Current Opinion in Oncology, vol. 14, no. 3, pp. 334-342, 2002
3. Department of Health Executive Yuan and ROC, Cancer Registry Annual Report in Taiwan Area, Department of Health, Executive Yuan, ROC, Taipei, Taiwan, 2006
4. P. Lothaire, E. de Azambuja, D. Dequanter et al., "Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation," Head & Neck, vol. 28, no. 3, pp. 256-269, 2006
5. A. D'Cruz, T. Lin, A. K. Anand et al., "Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelines," Oral Oncology, vol. 49, no. 9, pp. 872-877, 2013
6. A. K. Crombie, C. Farah, L. Tripcony,G. Dickie, and M. D. Batstone, "Primary chemoradiotherapy for oral cavity squamous cell carcinoma," Oral Oncology, vol. 48, no. 10, pp. 1014-1018, 2012
7. S. Ghoshal, I. Mallick, N. Panda, and S. C. Sharma, "Carcinoma of the buccalmucosa: analysis of clinical presentation, outcome and prognostic factors," Oral Oncology, vol. 42, no. 5, pp. 533-539, 2006
8. M. H. Larizadeh and M. Shabani, "Survival following non surgical treatments for oral cancer: a single institutional result," Asian Pacific Journal of Cancer Prevention, vol. 13, no. 8, pp. 4133-4136, 2012
9. M. Merlano, R. Corvo', G. Margarino et al., "Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. The final report of a randomized trial," Cancer, vol. 67, no. 4, pp. 915-921, 1991
10. M. Merlano, M. Benasso, R. Corvò et al., "Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck," Journal of the National Cancer Institute, vol. 88, no. 9, pp. 583-589, 1996
11. D. J. Adelstein, J. P. Saxton, P. Lavertu et al., "Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy," Journal of Clinical Oncology, vol. 20, no. 5, pp. 1405-1410, 2002
12. M. Teo, E. Karakaya, C. A. Young et al., "The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis," ClinicalOncology, vol. 25,no. 11,pp. 647-653, 2013
13. F. H. Igney and P. H. Krammer, "Death and anti-death: tumour resistance to apoptosis," Nature Reviews Cancer, vol. 2, no. 4, pp. 277-288, 2002
14. A. Oldberg, A. Franzen, and D. Heinegard, "Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence," Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 23, pp. 8819-8823, 1986
15. W. T. Butler, "Structural and functional domains of osteopontin," Annals of the New York Academy of Sciences, vol. 760, pp. 6-11, 1995
16. M. T. Gillespie, R. J. Thomas, Z.-Y. Pu, H. Zhou, T. J. Martin, and D. M. Findlay, "Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers," International Journal of Cancer, vol. 73, no. 6, pp. 812-815, 1997
17. T. Ue, H. Yokozaki, Y. Kitadai et al., "Co-expression of osteopontin and CD44v9 in gastric cancer," International Journal of Cancer, vol. 79, no. 2, pp. 127-132, 1998
18. J. Zhang, K. Takahashi, F. Takahashi et al., "Differential osteopontin expression in lung cancer," Cancer Letters, vol. 171, no. 2, pp. 215-222, 2001
19. M. Graessmann, B. Berg, B. Fuchs, A. Klein, and A. Graessmann, "Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3," Oncogene, vol. 26, no. 20, pp. 2840-2850, 2007
20. T. Gu, R. Ohashi, R. Cui et al., "Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer," Lung Cancer, vol. 66, no. 2, pp. 176-183, 2009
21. Y. Kita, S. Natsugoe, H. Okumura et al., "Expression of osteopontin in oesophageal squamous cell carcinoma," British Journal of Cancer, vol. 95, no. 5, pp. 634-638, 2006
22. Y.-S. Li, Z.-H. Deng, C. Zeng, and G.-H. Lei, "Role of osteopontin in osteosarcoma," Medical Oncology, vol. 32, article 449, 2015
23. M. Avirovíc, K. Matusan-Ilijas, G. Damante et al., "Osteopontin expression is an independent factor for poor survival in oral squamous cell carcinoma: a computer-assisted analysis on TMA sections," Journal of Oral Pathology & Medicine, vol. 42, no. 8, pp. 620-626, 2013
24. M. Bandopadhyay, A. Bulbule, R. Butti et al., "Osteopontin as a therapeutic target for cancer," Expert Opinion on Therapeutic Targets, vol. 18, no. 8, pp. 883-895, 2014
25. L. R. Rodrigues, J. A. Teixeira, F. L. Schmitt, M. Paulsson, and H. Lindmark-Mänsson, "The role of osteopontin in tumor progression and metastasis in breast cancer," Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 6, pp. 1087-1097, 2007
26. S. Jain, G. Chakraborty, and G. C. Kundu, "The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinaseC/c-Src/IB kinase /-dependent prostate tumor progression and angiogenesis," Cancer Research, vol. 66, no. 13, pp. 6638-6648, 2006
27. A. Karadag, K. U. E. Ogbureke, N. S. Fedarko, and L. W. Fisher, "Bone sialoprotein, matrix metalloproteinase 2, and v3 integrin in osteotropic cancer cell invasion," Journal of the National Cancer Institute, vol. 96, no. 12, pp. 956-965, 2004
28. I. Snitcovsky, G. M. Leitão, F. S. Pasini et al., "Plasma osteopontin levels in patients with head and neck cancer undergoing chemoradiotherapy," Archives of Otolaryngology-Head & Neck Surgery, vol. 135, no. 8, pp. 807-811, 2009
29. B. R. Winkelmann, K. von Holt, and M. Unverdorben, "Smoking and atherosclerotic cardiovascular disease: part I: atherosclerotic disease process," Biomarkers in Medicine, vol. 3, no. 4, pp. 411-428, 2009
30. M. Scatena, L. Liaw, and C. M. Giachelli, "Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 11, pp. 2302-2309, 2007
31. A. Prasse, M. Stahl, G. Schulz et al., "Essential role of osteopontin in smoking-related interstitial lung diseases," The American Journal of Pathology, vol. 174, no. 5, pp. 1683-1691, 2009
32. S. Raguz and E. Yagüe, "Resistance to chemotherapy: new treatments and novel insights into an old problem," British Journal of Cancer, vol. 99, no. 3, pp. 387-391, 2008
33. S. Fulda and K.-M. Debatin, "Apoptosis signaling in tumor therapy," Annals of the New York Academy of Sciences, vol. 1028, pp. 150-156, 2004
34. A. Haimeur, G. Conseil, R. G. Deeley, and S. P. C. Cole, "The MRP-related and BCRP/ABCG2multidrug resistance proteins: biology, substrate specificity and regulation," Current Drug Metabolism, vol. 5, no. 1, pp. 21-53, 2004
35. F. J. Sharom, "ABC multidrug transporters: structure, function and role in chemoresistance," Pharmacogenomics, vol. 9, no. 1, pp. 105-127, 2008
36. E. M. Leslie, R. G. Deeley, and S. P. C. Cole, "Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense," Toxicology and Applied Pharmacology, vol. 204, no. 3, pp. 216-237, 2005
37. C. C. Luedtke, M. D. McKee, D. G. Cyr et al., "Osteopontin expression and regulation in the testis, efferent ducts, and epididymis of rats during postnatal development through to adulthood," Biology of Reproduction, vol. 66, no. 5, pp. 1437-1448, 2002
38. I.-S. Hsieh,W.-H. Huang, H.-C. Liou,W.-J. Chuang, R.-S. Yang, and W.-M. Fu, "Upregulation of drug transporter expression by osteopontin in prostate cancer cells," Molecular Pharmacology, vol. 83, no. 5, pp. 968-977, 2013
39. C.-Y. Chien, H.-T. Tsai, L.-J. Su et al., "Aurora-A signaling is activated in advanced stage of squamous cell carcinoma of head and neck cancer and requires osteopontin to stimulate invasive behavior," Oncotarget, vol. 5, no. 8, pp. 2243-2262, 2014
40. A. D. Rapidis, M. Trichas, E. Stavrinidis et al., "Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up," Oral Oncology, vol. 42, no. 7, pp. 675-684, 2006
41. J. B. Vermorken, E. Remenar, C. Van Herpen et al., "Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer," The New England Journal of Medicine, vol. 357, no. 17, pp. 1695-1704, 2007
42. M. R. Posner, D. M. Hershock, C. R. Blajman et al., "Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer," The New England Journal of Medicine, vol. 357, no. 17, pp. 1705-1715, 2007.